We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/1/2021 13:40 | The herds still continue to reiterate the same with a man's 'Best Friend' Twitter - I ask again how many pre-clinical trials have demonstrated safety adequacy and then faltered? But billions and trillions are still highly likely right with such ferocious competition within BioPharma...Globally | rebelwithacause1 | |
21/1/2021 13:26 | https://twitter.com/ | aaron_r | |
21/1/2021 12:10 | 'HOPE' being the given word! I can hope for 'Everything' but it is not guaranteed now is it! ...But you still continue to miss the point or just resistant to listening. I iterate again (and no doubt will again!) - how many trials are abandoned following expansion due to untoward instances? - quite a few by my recollection! | rebelwithacause1 | |
21/1/2021 12:07 | hope to see very positive clinical trial data so we can expand the trial | yidarmytom | |
21/1/2021 12:02 | Confidence diminishing hey, I thought its just started, surely I'm not mistaken am I! | rebelwithacause1 | |
21/1/2021 11:58 | it's been a fun engagement but we're at the end of the road bud | yidarmytom | |
21/1/2021 11:48 | Brilliant buddy - I'm most grateful... ...But when you do 'Unfilter' not if realise I'm not SC but if you still don't believe it, read over both our comments and 'DisSect' the information as appropriate as they would in a clinical setting like yours, it may just help you realise that we are both very different... | rebelwithacause1 | |
21/1/2021 11:43 | rebs filtered, small crow filtered | yidarmytom | |
21/1/2021 11:32 | Hehe - seriously Tom, you would rather listen to the 'Mug' that is OldApache and all his palava...that is worrying! | rebelwithacause1 | |
21/1/2021 11:26 | agreed Mark, it's fairly obvious | yidarmytom | |
21/1/2021 11:10 | Rebelwithoutabrain is switching between his aliases now. Reb over to small crow then back to Reb again. Who does he think he's fooling. Such a sad pig of a man. | mark0419 | |
21/1/2021 11:08 | We beg to agree 100% Rebs, I am with you on that but to be fair I never said or implied it was - IF the data is good they will expand the trial (to your point earlier) and that could give a boost but it's an IF. hehe! | yidarmytom | |
21/1/2021 11:06 | Look, I am not clinically based but I do know absolutely nothing is guaranteed here... | rebelwithacause1 | |
21/1/2021 11:03 | misunderstand the products? Tiziana do not have any products so that shows wtf you know small crow...pmsl They have candidates in P1, 1b, & 2 trials but I doubt you have the first idea on the difference between them or the criteria you need to meet to get FDA approval to move from one phase to the next. | yidarmytom | |
21/1/2021 11:02 | 14% of pre-clinical trials are successful through to FDA approval. But we are not pre-clinical are we? What do you think the % is for P1 or P2 to get to P3, IND or NDA approval? | yidarmytom | |
21/1/2021 11:01 | yidarmy, so ... er .... how did such an expert manage to misunderstand the products of this one? And, perhaps your consultancy was in a non-clinical area? Managing the lift? | small crow | |
21/1/2021 10:59 | Global percentages would be a start Tom... Four years ago hey Lean, it would be helpful to assume the figures within the last couple of years when all things BioPharma have been blooming... ...And there you have it, not so promising right as Lean states! | rebelwithacause1 | |
21/1/2021 10:55 | In other words, 1 in 7 products managed to be utelised for the masses. Not a good percentage meethinks. | lean5gb | |
21/1/2021 10:54 | I used to do consultancy for a U.S. based CRO so yes, I think I know a bit about clinical trials..... | yidarmytom | |
21/1/2021 10:52 | RebelwithaCause121 Jan '21 - 10:39 - 12457 of 12462 0 0 0 So you're also aware of how many trials are abandoned following pre-initial success? Absolutely, how much detail would you like me to go into on an example? | yidarmytom | |
21/1/2021 10:52 | The 14% figures were admittedly 4 years old, and were for the product not to be sold on to the market. | lean5gb | |
21/1/2021 10:46 | "I'm a specialist Biotech Investor ..." LOL | small crow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions